Mepolizumab proved efficacious for eosinophilic granulomatosis with polyangiitis (EGPA, former Churg-Strauss) at the dosage of 300mg/4 weeks in the randomized controlled MIRRA trial. Few successful real-life experiences with the dosage approved for severe eosinophilic asthma (100mg/4 weeks) were recently reported. We retrospectively assessed the effectiveness and safety of mepolizumab 100 and 300mg/4 weeks in a large European EGPA cohort.

Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study / Bettiol, Alessandra; Urban, Maria Letizia; Dagna, Lorenzo; Cottin, Vincent; Franceschini, Franco; Del Giacco, Stefano; Schiavon, Franco; Neumann, Thomas; Lopalco, Giuseppe; Novikov, Pavel; Baldini, Chiara; Lombardi, Carlo; Berti, Alvise; Alberici, Federico; Folci, Marco; Negrini, Simone; Sinico, Renato Alberto; Quartuccio, Luca; Lunardi, Claudio; Parronchi, Paola; Moosig, Frank; Espígol-Frigolé, Georgina; Schroeder, Jan; Kernder, Anna Luise; Monti, Sara; Silvagni, Ettore; Crimi, Claudia; Cinetto, Francesco; Fraticelli, Paolo; Roccatello, Dario; Vacca, Angelo; Mohammad, Aladdin J; Hellmich, Bernhard; Samson, Maxime; Bargagli, Elena; Cohen Tervaert, Jan Willem; Ribi, Camillo; Fiori, Davide; Bello, Federica; Fagni, Filippo; Moroni, Luca; Ramirez, Giuseppe Alvise; Nasser, Mouhamad; Marvisi, Chiara; Toniati, Paola; Firinu, Davide; Padoan, Roberto; Egan, Allyson; Seeliger, Benjamin; Iannone, Florenzo; Salvarani, Carlo; Jayne, David; Prisco, Domenico; Vaglio, Augusto; Emmi, Giacomo; Silvestri, Elena; Mattioli, Irene. - In: ARTHRITIS & RHEUMATOLOGY. - ISSN 2326-5191. - ELETTRONICO. - (2021), pp. 0-0. [10.1002/art.41943]

Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study

Bettiol, Alessandra;Urban, Maria Letizia;Baldini, Chiara;Parronchi, Paola;Bargagli, Elena;Fiori, Davide;Bello, Federica;Fagni, Filippo;Prisco, Domenico;Vaglio, Augusto;Emmi, Giacomo;Silvestri, Elena
Membro del Collaboration Group
;
Mattioli, Irene
Membro del Collaboration Group
2021

Abstract

Mepolizumab proved efficacious for eosinophilic granulomatosis with polyangiitis (EGPA, former Churg-Strauss) at the dosage of 300mg/4 weeks in the randomized controlled MIRRA trial. Few successful real-life experiences with the dosage approved for severe eosinophilic asthma (100mg/4 weeks) were recently reported. We retrospectively assessed the effectiveness and safety of mepolizumab 100 and 300mg/4 weeks in a large European EGPA cohort.
2021
0
0
Bettiol, Alessandra; Urban, Maria Letizia; Dagna, Lorenzo; Cottin, Vincent; Franceschini, Franco; Del Giacco, Stefano; Schiavon, Franco; Neumann, Thom...espandi
File in questo prodotto:
File Dimensione Formato  
Arthritis Rheumatology - 2021 - Bettiol - Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis A European.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Creative commons
Dimensione 704.03 kB
Formato Adobe PDF
704.03 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1242886
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 83
  • ???jsp.display-item.citation.isi??? 77
social impact